CDK Inhibitors approved by PBAC 20 April 2018
CDK Inhibitors approved by the Pharmaceutical Benefits Advisory Committee (PBAC) but cost is still an issue. See the link below for further information https://www.bcna.org.au/news/2018/04/cdk-i...
Forum Discussion
Giovanna,
Thank you for that piece of the access puzzle on Pfizer.
Lesleyb - you are right - it's a little bit of a pickle for PBS ...not so little.
This is from late 2017 following Asco - published as Pfizer news.
http://press.pfizer.com/press-release/updated-data-phase-3-trial-ibrance-palbociclib-plus-letrozole-er-her2-metastatic-breas
I draw attention to the paragraph that says
In the U.S., IBRANCE is indicated for the treatment of HR+, HER2- advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women, or fulvestrant in women with disease progression following endocrine therapy.Dec 6, 2017
There is a catch - fulvestrant ( Faslodex ) is not PBS approved in Australia, despite being an effective hormonal therapy and being around for more then 5 years. As far as I can tell Astra Zeneca DID NOT submit to PBAC thus fulvestrant is only available at around $800 a month or a start up compassionate access.
The question remains what do the women who need Faslodex/Ibrance as a line of therapy do??
Giovanna - is absolutely right WE should ALWAYS check all information with your treating oncologist to work out how it pertains to our treatment plan.
Thank you for that piece of the access puzzle on Pfizer.
Lesleyb - you are right - it's a little bit of a pickle for PBS ...not so little.
This is from late 2017 following Asco - published as Pfizer news.
http://press.pfizer.com/press-release/updated-data-phase-3-trial-ibrance-palbociclib-plus-letrozole-er-her2-metastatic-breas
I draw attention to the paragraph that says
In the U.S., IBRANCE is indicated for the treatment of HR+, HER2- advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women, or fulvestrant in women with disease progression following endocrine therapy.Dec 6, 2017
There is a catch - fulvestrant ( Faslodex ) is not PBS approved in Australia, despite being an effective hormonal therapy and being around for more then 5 years. As far as I can tell Astra Zeneca DID NOT submit to PBAC thus fulvestrant is only available at around $800 a month or a start up compassionate access.
The question remains what do the women who need Faslodex/Ibrance as a line of therapy do??
Giovanna - is absolutely right WE should ALWAYS check all information with your treating oncologist to work out how it pertains to our treatment plan.